Vitadio is a pioneering company in prescription digital therapeutics focused on reversing insulin resistance through AI-driven lifestyle modification.

Vitadio empowers people to restore their cardiometabolic health by creating digital therapies that treat the underlying causes of chronic conditions such as type 2 diabetes, not just the symptoms. The therapies are designed to improve health one habit at a time without side effects.

The platform provides personalised therapy with smart nudges and personalised goals, using evidence-based content and complex user data. It includes AI-driven real-time feedback comparable to a human dietitian and offers proactive human support including a personal dietitian and social networking features within the app.

Vitadio's digital therapeutics show clinically proven outcomes comparable to modern antidiabetic drugs, with improved patient adherence and significant improvements in HbA1c levels and weight reduction as demonstrated in peer-reviewed studies.

Founded in 2019, Vitadio has headquarters in Prague and Berlin, offering digital therapeutics for type 2 diabetes and prediabetes across three European countries with ongoing expansion efforts.